Recurrence of CDI occurred in 13 ( 30 % ) of 43 placebo patients and 14 ( 11 % ) of 125 NTCD-M3 patients ( odds ratio [ OR ] , 0.28 ; 95 % CI , 0.11-0 .69 ; P = .006 ) ; the lowest recurrence was in 2 ( 5 % ) of 43 patients receiving 10 ( 7 ) spores/d for 7 days ( OR , 0.1 ; 95 % CI , 0.0-0 .6 ; P = .01 vs placebo ] ) .